AVID 100

Drug Profile

AVID 100

Alternative Names: AVID 100

Latest Information Update: 06 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Formation Biologics
  • Developer Formation Biologics; National Research Council Canada
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor modulators; Epidermal growth factor receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Breast cancer; Head and neck cancer

Most Recent Events

  • 01 Feb 2017 Phase-I/II clinical trials in Solid tumours (Metastatic disease) in USA (Parenteral) (NCT03094169)
  • 29 Nov 2016 Pharmacodynamics data from a preclinical study in Breast and Head and neck cancer presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top